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Introduction:  Juvenile  myoclonic  epilepsy  (JME)  is  a  genetic  generalized  epilepsy  syndrome.
Under appropriate  antiepileptic  drugs  (AED)  up  to  85%  of  patients  become  seizure-free,  but
many may  have  a  relapse  after  AED  withdrawal.
Methods:  We  retrospectively  studied  242  patients  with  JME  at  the  Department  of  Neurology,
Medical University  Innsbruck,  Austria  (1975—2006).  We  analyzed  age  at  seizure  onset,  age  at
last follow  up,  seizure  types,  photosensitivity,  seizure  outcome  and  neuroimaging  ﬁndings;
inclusion  criterion  was  a  medical  treatment  period  of  >2  years;  exclusion  criteria  were  trau-
matic or  infectious  brain  injury  before  the  onset  of  JME  and/or  gross  structural  pathology  on
neuroimaging.
Results: We  identiﬁed  175  patients  (111  women)  with  a  median  age  at  seizure  onset  of  15
years, (range  3—46)  and  a  median  age  at  follow-up  (FU)  of  38  years  (range  14—87;  median  FU  8
years, range  2—38).  Fourteen  percent  showed  (24/175)  photosensitivity  on  routine  EEG.  Seizure
outcome: 62%  (109/175)  were  seizure-free  of  myoclonic  seizures  (MS),  generalized  tonic  clonic
seizures (GTCS)  and  absence  seizures  (AS)  for  >1  year,  and  53%  (94/175)  for  >2  years,  including
16 patients  (9%)  without  AEDs.  Thirty-one  percent  (54/175)  were  seizure-free  between  2and
5 years,  15%  (26/175)  between  6  and  10,  and  8%  (14/175)  >10  years;  38%  (66/175)  were  not
seizure-free.  Not  seizure-free  patients  had  more  often  MS,  AS  and  GTCS  within  the  ﬁrst  year  of
epilepsy than  those  who  were  seizure-free  at  last  FU  (11%  vs.  3%,  Chi2 =  4.679,  df  =  1,  p  =  0.043).
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Seizure-free  patients  had  more  of
ing seizure-free  (37%  vs.  15%,  p  =  0
persisted.
Conclusions:  JME  does  not  alway
remain seizure-free  without  AEDs
long-term  seizure  control.
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uvenile  myoclonic  epilepsy  (JME)  is  a  common  age  related
enetic  generalized  epilepsy  syndrome  and  accounts  for
p  to  10%  of  all  epilepsies  (Janz  and  Christian,  1957;
anz,  1969;  Janz,  1985).  Seizures  typically  manifest  in
dolescence,  between  13  and  19  years.  The  syndrome  is
haracterized  by  myoclonic  seizures  (MS),  generalized  tonic
lonic  seizures  (GTCS)  and  absence  seizures  (AS)  (Janz
nd  Christian,  1957)  Interictal  EEG  abnormalities  comprise
eneralized  polyspike  —  waves  at  4—6  Hz  with  photosen-
itivity  in  about  30%  of  cases  (Janz,  1985)  and  up  to
0%  after  prolonged  photic  stimulation  (Appleton  et  al.,
000).  Under  appropriate  antiepileptic  drug  (AED)  treat-
ent  the  majority  of  patients  will  enter  remission  (Janz
nd  Christian,  1957;  Panayiotopoulos  et  al.,  1994;  Gelisse
t  al.,  2001;  Martinez-Juarez  et  al.,  2006;  Baykan  et  al.,
008;  Camﬁeld  and  Camﬁeld,  2009;  Geithner  et  al.,  2012;
enf  et  al.,  2013).  However,  after  AED  withdrawal,  the
elapse  rate  may  be  as  high  as  91%  (Janz,  1985;  Shinnar
t  al.,  1994;  Delgado-Escueta  et  al.,  1997;  Kleveland  and
ngelsen,  1998;  Chakravarty  et  al.,  2007).  Only  few  stud-
es  focused  on  long-term  seizure  outcome  of  this  syndrome
Martinez-Juarez  et  al.,  2006;  Baykan  et  al.,  2008;  Camﬁeld
nd  Camﬁeld,  2009;  Geithner  et  al.,  2012;  Senf  et  al.,
013).  The  decision  about  when  to  start  tapering  off
edication  or  eventually  withdraw  AEDs  is  discussed  contro-
ersially  in  the  literature.  Many  authors  recommend  lifelong
reatment  (Dreifuss,  1989;  Delgado-Escueta  and  Enrile-
acsal,  1984;  Panayiotopoulos  et  al.,  1994;  Penry  et  al.,
989;  Grünewald  and  Panayiotopoulos,  1993;  Kleveland  and
ngelsen,  1998;  Martinez-Juarez  et  al.,  2006;  Meador,  2008).
n  view  of  chronic  AED  toxicity,  which  may  be  a  special
roblem  with  valproic  acid  (VPA)  (Genton  et  al.,  2001;
uef  et  al.,  2002;  Luef  et  al.,  2004;  Rinnerthaler  et  al.,
005;  Teich  et  al.,  2004;  Isojärvi  et  al.,  1993;  Hirsch
t  al.,  2003),  which  is  still  regarded  as  the  most  effec-
ive  drug  in  this  syndrome,  a  lifelong  treatment  has  to
e  carefully  weighted  against  the  risks  of  seizure  recur-
ence.
The  aim  of  our  study  was  to  analyse  the  long-term  seizure
utcome  of  patients  with  JME  in  a  large  hospital  based
ohort  of  a  single  center.
ethods
tudy  design  and  setting:  Retrospective  hospital  based
bservational  study  with  a  cross  sectional  design  performed
n  a  large  outpatient  clinic  of  a  university  hospital  as  the
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ten  MS  and  GTCS  as  last  seizure  types  in  the  year  before  becom-
.003),  whereas  in  not  seizure-free  group  MS  only  and  GTCS  only
s  need  lifelong  treatment,  as  a  substantial  minority  of  patients
.  AS,  MS  and  GTCS  at  onset  of  the  disease  are  indicators  of  poor
y  Elsevier  B.V.  This  is  an  open  access  article  under  the  CC  BY-
mmons.org/licenses/by-nc-nd/3.0/).
All  data  of  patients  treated  at  the  seizure  outpatient
linic  at  the  Department  of  Neurology,  Medical  University
nnsbruck,  Austria  between  1975  and  2006  were  entered
rospectively  into  a database.  We  identiﬁed  242  patients
ith  the  diagnosis  of  JME  in  this  database.  Inclusion  criteria
ere:  (1)  a  diagnosis  of  JME,  based  on  the  criteria  of  the
nternational  League  against  Epilepsy  (ILAE),  (Commission
n  Classiﬁcation  and  Terminology  of  ILAE,  1989);  (2)  a  medi-
al  treatment  period  of  more  than  2  years  in  our  outpatient
linic.  Exclusion  criteria  were:  (1)  traumatic  or  infectious
rain  injury  before  the  onset  of  JME  and  (2)  gross  structural
athology  on  neuroimaging  (CT/MRI).  Fifty-eight  out  of  242
atients  had  a  treatment  period  of  less  than  2  years,  seven
atients  died  and  charts  of  two  patients  were  missing.
The  national  death  registry  records  only  the  ICD  coded
ondition  judged  by  the  reporter  to  be  the  primary
ause,  with  no  record  of  comorbidities/contributors.  These
ere  chronic  kidney  disease  (two  patients);  mental  and
ehavioral  disorders  due  to  use  of  alcohol  (2),  cardiomy-
pathy  (1),  poisoning  by  unspeciﬁed  drug  or  medicinal
ubstance  (1)  and  grand  mal  status  epilepticus  (1).  Thus,
75  patients  remained  for  further  analysis.  We  extracted
linical  information  including  age  at  seizure  onset,  age
t  the  last  visit  in  the  outpatient  clinic,  gender,  ﬁrst
ocumented  seizure  type  at  onset  (during  the  ﬁrst  year
f  disease),  last  documented  seizure  type  (during  the
ast  year  of  active  epilepsy)  and  photosensitivity  (as
ssessed  by  routine  EEG  recordings  at  any  time  during
he  course  of  disease).  In  addition  data  on  neuroimag-
ng  (MRI,  CT),  febrile  convulsions  (FC),  family  history  of
pilepsy,  neurological  examination,  response  to  medical
reatment  with  various  AEDs  and  seizure  outcome  with  or
ithout  AED  therapy  were  extracted  from  the  patients’
harts.
The  endpoint  of  our  study  was  deﬁned  as  the  seizure
utcome  at  the  last  visit  in  our  outpatient  clinic.  Three  cat-
gories  were  deﬁned:  (1)  seizure-free  for  more  than  one  and
ess  than  or  equal  to  2  years,  (2)  seizure-free  for  more  than
 years  and  (3)  not  seizure-free.
tatistical  analysis
ata  processing  and  analysis  were  performed  with  SPSS
ersion  12.0  for  Windows.  The  statistical  methods  were
escriptive  statistic  Chi2 test  for  categorical  variables  for
roup  comparisons  and  t-tests  for  continuous  variables.  Sig-
iﬁcance  was  deﬁned  as  p-value  of  ≤0.05.  Binary  linear
egression  analysis  was  used  to  identify  predictive  factors
or  seizure  outcome.
Non-parametric  data  (age  at  seizure  onset,  age  at
ast  visit,  etc.)  were  analysed  by  Kruskal—Wallis  and
Seizure  outcome  in  juvenile  myoclonic  epilepsy  
Table  1  Demographic  data.
Patients  N  =  175  (111  women)
Median  age  at  seizure  onset
Median  age  at  follow  up
15  years  (range  3—46)
38  years  (range  14—87)
Median  observation  period  8  years  (range  2—38)
Family  history  of  epilepsy  41%  (71/175)













APhotosensitivity 14%  (24/175)
Mann—Whitney  tests  for  multiple  and  pair-wise  compar-
isons,  respectively  (Tables  1—6).
ResultsPatients
We  analysed  175  patients  (111  women),  median  age  at




Table  2  Duration  of  seizure-freedom  at  the  last  follow-up  in  pat
of more  than  one  year  seizure-free  patients  =  109).










N =  (%)
—  6/109  (6)  7/109  (6)  
Abbreviations: FU = Follow up; JME = Patients with juvenile myocl
pts = Patients.
Table  3  Outcome  and  documented  seizure  types  at  ﬁrst  year  of  
Seizure-free  ≥1year  n  (%
N =  109  (62%)
Myoclonic  seizures  only  28  (26)  
Generalized tonic  clonic
seizures  only
25  (23)  
Absence seizures  only  10  (9)  
Myoclonic seizures  +  absence
seizures
2 (2)  
Myoclonic
seizures +  generalized  tonic
clonic  seizures
36  (33)  
Myoclonic
seizures +  generalized  tonic
clonic  seizures  +  absence
seizures
3 (3)  
Absence  seizures  +  generalized
tonic  clonic  seizures
5  (4)  
* Statistically signiﬁcant at p ≤ 0.05.1819
t  the  last  follow  up  was  38  years  (range  14—87)  with  a
edian  observation  period  of  8  years  (range  2—38).  Mean
pilepsy-duration  was  24  years  (SD  ±  14.2),  median  23  years
range  3—73).  Seventy-one  (41%)  patients  had  a  positive
amily  history  of  epilepsy;  seven  (4%)  had  a  history  of  febrile
onvulsions.
Twenty-four  patients  (14%)  showed  photosensitivity  on
outine  EEG  recordings  (Table  1).
verall  seizure  outcome
ixty-two  percent  (109/175)  of  patients  were  completely
eizure-free  more  than  one  year  under  AED  treat-
ent,  53%  (94/175)  were  seizure-free  for  more  than
 years,  including  16  patients  (9%)  without  taking  any
ED.
Thirty-one  percent  (54/175)  of  patients  were  seizure-
ree  between  2  and  5  years,  15%  (26/175)  between  6 and
0  years  and  8%  (14/175)  more  than  10  years.
Thirty-eight  percent  (66/175)  were  not  seizure-free
espite  appropriate  AED  treatment  (Table  2).













4/109  (13)  94/175  (54)  78/175  (45)  16/175  (9)
4/109  (4)  17/175  (10)  11/175  (6)  6/175  (3)
onic epilepsy; f = Female; m = Male; AED = Antiepileptic drug;
epilepsy.
) Not  seizure-free  ≥1year  n  (%)
N =  66  (38%)
p*
14  (21)  0.585
15  (23)  1.000
5  (8)  0.788
3  (4)  0.367
16  (24)  0.396
7  (11)  0.043*
6  (9)  0.335
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Table  4  Outcome  and  documented  seizure  types  in  the  year  before  becoming  seizure-free  or  seizure  types  of  persisting  seizures
at follow  up.
Seizure-free  ≥1year  n  (%)
N =  109  (62%)
Not  seizure-free  ≥1year  n  (%)
N =  66  (38%)
p*
Myoclonic  seizures  only  23  (21)  23  (35)  0.052
Generalized  tonic  clonic
seizures  only
30  (28)  17  (26)  0.861
Absence seizures  only 5  (4) 2  (3) 0.712
Myoclonic
seizures  +  absence
seizures
2  (2) 4  (6) 0.200
Myoclonic
seizures  +  generalized
tonic  clonic  seizures
40  (37)  10  (15)  0.003*
Myoclonic
seizures  +  generalized
tonic  clonic
seizures  +  absence
seizures
4  (4)  4  (6)  0.478
Absence
seizures +  generalized
tonic  clonic  seizures



















(* Statistically signiﬁcant at p ≤ 0.05.
eizure  outcome  and  seizure  types  in  the  ﬁrst  year
f epilepsy
atients  who  were  not  seizure-free  at  the  last  follow  up  were
igniﬁcantly  more  likely  to  have  had  all  three  seizure  types
ithin  the  ﬁrst  year  of  their  epilepsy  compared  to  seizure-
ree  patients  (≥1  year  seizure-free  at  the  last  follow  up;
eizure-free  3%  vs.  not  seizure-free  11%,  df  =  1,  p  =  0.043)
Figure  1,  Table  3).eizure  outcome  and  persisting  seizure  types
eizure-free  patients  were  signiﬁcantly  more  likely  to  have





Table  5  Antiepileptic  drug  treatment  and  outcome,  multiple  ant
Antiepileptic  drugs  >2  years  seizure-free  n  (%
N total  =  94  patients
Valproic  acid  62/94  (66)  
Carbamazepine  1/94  (1)  
Topiramat 3/94  (3)  
Levetiracetam  8/94  (9)  
Lamotrigin 2/94  (2)  
Primidon  6/94  (6)  
Clonazepam  1/94  (1)  
Phenobarbital  2/94  (2)  
Zonisamide  1/94  (1)  
Ethosuximide  —  
No antiepileptic  drug  treatment  16/94  (17)  
* Statistically signiﬁcant at p ≤ 0.05.eizure-free  (37%  vs.  15%,  p  =  0.003),  whereas  in  the  not
eizure-free  group  MS  only  and  GTCS  only  tend  to  persist
Table  4).
ntiepileptic  drug  treatment
he  majority  of  patients  (66%  of  seizure-free  and  60%  of
hose  with  persisting  seizures)  were  on  VPA  monother-
py.  Other  drugs  used  in  monotherapy  were  levetiracetam
LEV),  topiramat  (TPM),  primidon  (PRM)  or  lamotrigin  (LTG).
atients  taking  LEV,  TPM  or  PRM  did  not  differ  in  seizure
utcome.  In  contrast,  patients  receiving  LTG  became  less
requently  seizure-free  (15%;  p  = 0.024).  Three  percent
f  patients  (one  patient  of  the  seizure-free  group  and
iepileptic  drugs  per  patient  are  possible.
) Not  seizure-free  n  (%)
N  total  =  81  patients
p*
49/81  (60)  0.529
4/81  (5)  0.183
7/81  (9)  0.190
13/81  (16)  0.162
9/81  (11)  0.024*
8/81  (10)  0.417
1/81  (1)  1.000
5/81  (6)  0.251
1/81  (1)  1.000
2/81  (2)  0.212
3/81  (4)  0.003*
Seizure  outcome  in  juvenile  myoclonic  epilepsy  1821
Table  6  Overview  long-term  outcome  studies.  Abbreviations:  MS  =  Myoclonic  seizure;  AS  =  Absence  seizure;  GTCS  =  Generalized
tonic clonic  seizure;  JME  =  Patients  with  juvenile  myoclonic  epilepsy;  FU  =  Follow  up;  sd  =  Standard  deviation;  CAE  =  Childhood
absence epilepsy.
Martinez-Juarez
et  al.,  2006.  Brain





Geithner  et  al.,
2012.  Epilepsia










N= 222  patients  48  patients  23  patients  31  patients  66  patients
Mean follow-up  12.4  years
(range  1—41)
19.6  ±  5.7  years  25.8  ±  2.4  years  39.1  years
(sd  ±  11.9;  range
25—63)
44.6  years






deﬁnition  of  time
Benign  course:
no  GTCS  and  <  2
MS/month
No  exact
deﬁnition  of  time





Classic  JME:  58%
(93/161)
seizure-free
(mean  FU  12.4  yrs;





JME  ±  adolescent
onset  pycnoleptic
AS:  56%  (10/18)
seizure-free
(mean  FU  13.4
years;  range  5—26)
JME  and  astatic
seizures:  62%
(5/8)  seizure-free

































duration  5  years
25%  (6/24)





years  (SD  ±  8.01,
16.7%  (11/66)
patients,  at  least











Bfour  of  the  not  seizure-free  group)  received  temporarily
carbamazepine  (CBZ)  once  in  their  medical  history.  At  FU
none  of  them  had  CBZ  anymore.  Eight  percent  of  patients
were  on  polytherapy  (Table  5).
Nine  percent  (16  patients)  of  the  patients  were  seizure-
free  without  any  AED-therapy.
The  ﬁrst  documented  seizure  types  of  these  16  patients
were  MS  only  in  46%  of  patients,  AS  only  in  26%,  GTCS  only  in
8%,  AS  and  GTCS  in  8%,  AS  and  MS  in  4%  and  all  three  seizure
types  in  8%  of  the  patients.Discussion
In  this  long-term  study  with  an  observation  period  of  up  to





f  all  seizure  types  for  more  than  one  —  and  53%  of  patients
or  more  than  2  years.  Nine  percent  of  all  patients  were
eizure-free  for  more  than  2  years  without  any  AED,  38%
f  patients  had  no  seizure  control.  The  presence  of  AS,  MS
nd  GTCS  within  the  ﬁrst  year  of  epilepsy  was  associated
ith  poor  long  term  seizure  control  (seizure-free  3%  vs.  not
eizure-free  11%,  df  =  1,  p  =  0.043).
In  contrast  to  the  commonly  held  belief,  that  JME
equires  lifelong  treatment  we  identiﬁed  patients  with
ood  seizure  outcome  based  on  the  occurrence  of  different
eizure  types  (Dreifuss,  1989;  Delgado-Escueta  and  Enrile-
acsal,  1984;  Panayiotopoulos  et  al.,  1994;  Penry  et  al.,
989;  Grünewald  and  Panayiotopoulos  1993;  Kleveland  and
ngelsen,  1998;  Martinez-Juarez  et  al.,  2006;  Meador,  2008).
n  the  seminal  description  of  JME  by  Janz  and  Christian
1957),  43%  of  patients  had  MS  as  ﬁrst  seizure  type
1822  J.  Höﬂer  et  al.











































































Jigure  1  Seizure  types  in  the  1st  year  of  epilepsy.  Abbreviatio
S =  Absence  seizures; * =  Statistically  signiﬁcant.
ersisting  for  several  months  or  years;  32%  had  MS  and  GTCS;
5%  had  GTCS  as  the  ﬁrst  seizure  type  followed  by  MS  after
everal  years  (Janz  and  Christian,  1957).  However,  they  did
ot  report  on  different  outcomes  depending  on  the  type
f  the  ﬁrst  seizure  and  the  evolution  at  the  early  phase
f  the  disease.  In  a  retrospective  study  of  the  Marseille
roup,  patients  with  a  lifetime  history  of  all  three  seizure
ypes  were  signiﬁcantly  more  often  not  seizure-free  (Gelisse
t  al.,  2001).  Another  prospective  study  (Guaranha  et  al.,
011)  has  also  conﬁrmed  this  as  a  negative  predictor.  Two
ther  studies  did  not  ﬁnd  any  association  between  seizure
ypes  in  JME  and  outcome  (Baykan  et  al.,  2008;  Geithner
t  al.,  2012).
In  our  study,  AS  had  a  tendency  to  remit,  while  MS  and
TCS  persisted  longer.  MS  and  GTCS  were  the  most  prevailing
ombination  of  seizure  types  in  those  who  became  eventu-
lly  seizure-free  (seizure-free  37%  vs.  not  seizure-free  15%,
 =  0.003).
Only  few  patients  had  MS  only:  the  occurrence  varies
rom  1%  in  our  study  to  11.7%  in  an  observational  study
Canevini  et  al.,  1992).  Janz  and  Christian  described  an
ntagonism  of  MS  and  GTCS:  some  patients  had  more  iso-
ated  MS  and  less  frequently  GTCS  preceded  by  MS,  the  other
roup  of  patients  had  more  GTCS  preceded  by  MS  and  rare
solated  MS.  The  predominance  of  isolated  MS  was  regarded
s  indicator  of  good  prognosis  of  seizure  outcome  (Janz  and
hristian,  1957).  The  total  number  of  GTCS  was  not  pre-
ictive  in  two  other  studies  (Baykan  et  al.,  2008;  Geithner
t  al.,  2012).
In  our  study  14%  (24/175)  of  patients  showed  photo-
ensitivity,  71%  (17/24)  of  them  were  seizure-free.  In  the
iterature  the  number  varies  from  8%  (Canevini  et  al.,
992)  to  90%  (Appleton  et  al.,  2000),  as  reported  in  a
eview  from  Kasteleijn-Nolst  Trenité  et  al.  (2013).  Respon-
ible  for  this  different  prevalence  are  factors  like  sex
photoparoxysmal  response  was  mainly  found  in  female,
asteleijn-Nolst  Trenité,  1989),  medication  (VPA  is  effec-
ive  in  patients  with  photoparoxysmal  response,  Jain  et  al.,
997),  time  of  EEG  (there  seems  to  be  a  higher  sensibility
f  EEG  in  the  morning,  Labate  et  al.,  2007),  methodology
f  photic  stimulation  (a  continuous  performance  for  up  to
 min  seems  to  increase  the  prevalence  of  photoparoxysmal
s
l
oS  =  Myoclonic  seizure;  GTCS  =  Generalized  tonic  clonic  seizures;
esponse,  Appleton  et  al.,  2000)  and  occurrence  of
leep  deprivation  (Scollo-Lavizzari  and  Scollo-Lavizzari,
974).
Consistent  with  the  ﬁndings  of  other  studies  (Baykan
t  al.,  2008;  Geithner  et  al.,  2012)  the  presence  of  pho-
osensitivity  in  our  study  was  not  considered  as  a  prognostic
actor.
A  prospective  study  showed  the  implication  of  reﬂex
raits  (eye-closure,  intermittent  photic  stimulation,  neu-
opsychological  tasks  like  mental  calculations,  language  and
raxis  induction).  In  ﬁve  patients  seizures  were  triggered
y  intermittent  photic  stimulation  and  none  were  seizure-
ree  compared  to  18.5%  of  those  without  such  seizures
p  =  0.005).  Similarly  six  patients  with  eye  closure  induced
eizures  had  a  poor  seizure  outcome  (21.4%  vs.  0.0%,
 = 0.025)  (Guaranha  et  al.,  2011).
So  far  ﬁve  studies  focused  on  the  long-term  evolution  of
eizure  types  in  JME  (Martinez-Juarez  et  al.,  2006;  Baykan
t  al.,  2008;  Camﬁeld  and  Camﬁeld,  2009;  Geithner  et  al.,
012;  Senf  et  al.,  2013). In  these  studies,  the  outcomes
aried  from  66%  (32/48)  of  patients  with  a benign  course
Baykan  et  al.,  2008: mean  follow-up  39.1  years  ±  11.9;
ange  25—63)  up  to  78%  (18/23)  (Camﬁeld  and  Camﬁeld,
009:  mean  follow-up  25.8  ±  2.4  years;  range  20—30  years),
7.7%  (21/31)  seizure-free  patients  (Geithner  et  al.,  2012:
ean  follow-up  39.1  ±  11.9;  range  25—63  years)  and  59.1%
39/66)  (Senf  et  al.,  2013: mean  follow-up  44.6  ±  13.7;
ange  20—69  years).  In  a  multicenter  long-term  follow-up
tudy  with  a subgroup  analysis  on  different  seizure  types,
eizure-freedom  was  found  in  58%  patients  with  classical  JME
93/161  patients;  mean  follow-up  12.4  years;  range  1—41
ears),  9%  patients  with  childhood  absence  epilepsy  evolv-
ng  into  JME  (3/35  patients;  follow-up  from  5  to  52  years),
6%  patients  with  JME  and  adolescent  onset  pyknoleptic
bsences  (10/18  patients;  mean  follow-up  13.4  years;  range
—26)  and  62%  patients  with  JME  and  astatic  seizures  (5/8
atients;  mean  follow-up  11.1  years;  range  3—18)  (Martinez-
uarez  et  al.,  2006).According  to  literature  the  rate  of  seizure  freedom  in  our
tudy  (53%  seizure-free  patients  for  more  than  2  years)  was
ow.  One  possible  reason  could  be  the  retrospective  design
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fail  coming  to  the  follow-up.  Comparing  to  Martinez-Juarez
et  al.  (2006)  our  outcome  correlates  to  the  ‘‘classical  JME’’
subgroup.  Maybe  the  other  subgroups  were  underdiagnosed
in  our  population.  Finally  in  a  specialized  clinic,  there  is  a
higher  proportion  of  difﬁculty  to  treat  patients.
The  decision  when  to  start  tapering  off  or  eventually
withdraw  AEDs  is  discussed  controversially,  and  so  far  there
is  no  reliable  prognostic  marker.  Previous  studies  reported
following  numbers  of  seizure-free  patients  without  AEDs:
Baykan  et  al.  (2008)  —  8%  (4/48)  of  patients,  mean  5  years
without  AEDs;  Geithner  et  al.  (2012)  —  19%  (6/31)  of  patients
(mean  duration  19.2  years;  SD  ±  8.01,  range  8—30);  Senf
et  al.  (2013)  —  16.7%  (11/66)  of  patients  (at  least  5  years);
Camﬁeld  and  Camﬁeld  (2009)  —  25%  (6/24  patients,  dura-
tion  for  5—23  years);  Martinez-Juarez  et  al.  (2006)  —  9%
(8/93)  of  patients  with  classic  JME  (duration  1—11  years);
(Martinez-Juarez  et  al.,  2006;  Baykan  et  al.,  2008;  Camﬁeld
and  Camﬁeld,  2009;  Geithner  et  al.,  2012;  Senf  et  al.,  2013)
(Table  6).
In our  study  the  presence  of  all  three  seizure  types  (MS,
AS  and  GTCS)  within  the  ﬁrst  year  of  JME  onset  predicted
a  poor  seizure  outcome.  The  recognition  of  this  progno-
stic  marker  is  of  major  clinical  value  when  the  decision  to
withdraw  AEDs  has  to  be  made.
According  to  the  literature  (Janz  and  Christian,  1957)
patients  with  MS  only  at  JME  onset  followed  later  by  GTCS
may  have  a  more  favorable  prognosis.  In  our  study  77%
(135/175)  of  the  total  patient  cohort  had  MS  and  later  GTCS
in  the  ﬁrst  year  of  epilepsy.  The  majority  (66%;  89/135)  of
patients  had  a  benign  course  and  was  seizure-free  at  the  last
follow-up.
To  predict  the  clinical  course  of  JME  poses  a  challenge  as
only  few  reliable  clinical  prognostic  markers  are  known.  One
well  described  marker  is  the  relationship  between  psychi-
atric  comorbidity  in  JME  and  drug  resistance  (Gelisse  et  al.,
2007;  Trinka  et  al.,  2006;  Baykan  et  al.,  2008;  De  Araújo
Filho  et  al.,  2008).  Another  positive  prognostic  factor  seems
to  be  MS  only  at  onset  (Jain  et  al.,  1997).  In  our  study,  two
out  of  16  patients  who  were  seizure-free  without  AEDs  had
MS  only  at  the  last  follow-up.
However,  it  would  be  necessary  to  have  clinical  or  bio-
logical  prognostic  factors  in  the  early  stage  of  a  disease.
Until  now,  clinical  markers  which  are  easy  to  evaluate  like
photoparoxysmal  response,  family  history  of  epilepsy,  sex,
age  at  onset  of  seizures,  neuroimaging  data,  delayed  diag-
nosis  and  total  number  of  GTCS  could  not  be  identiﬁed  as
prognostic  factors  (Gelisse  et  al.,  2001;  Baykan  et  al.,  2008;
Geithner  et  al.,  2012).
A  prospective  study  showed  the  implication  of  reﬂex
traits  (eye-closure,  intermittent  photic  stimulation,  neu-
ropsychological  tasks  like  mental  calculations,  language  and
praxis  induction)  on  prognosis.  Patients  with  precipitant
factors  in  praxis  induction  and  language  were  signiﬁcant
less  seizure-free.  There  was  no  correlation  between  the
presence  of  focal  EEG  abnormalities  and  seizure  out-
come,  but  interestingly  there  was  an  association  between
focal  EEG  abnormalities  and  the  type  of  reﬂex  traits.  The
majority  of  patients  with  frontal  EEG  abnormalities  had
praxis  induction,  one  patient  with  occipital  abnormalities
was  photosensitive  and  all  three  patients  with  temporal
abnormalities  had  psychiatric  disorders  (Guaranha  et  al.,
2011).
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The  major  limitation  of  our  study  is  the  retrospective
ature  with  possibly  missing  information  in  the  patients’
harts.  Due  to  the  lack  of  consistent  criteria  in  terms  of
apering  off  medication,  there  would  always  be  a  bias
owards  a  longstanding  treatment  and  the  true  proportion  of
omplete  seizure-free  patients  without  medication  cannot
e  assessed.  In  fact,  we  propose  that  a  long-term  seizure-
reedom  of  5  years  should  be  achieved.
As  discussed  by  Geithner  et  al.  (2012)  most  of  the  follow-
p  studies  including  ours  represent  only  easy-to-follow
atients.  In  face  of  the  known  underlying  psychological
athology  with  behavioral  abnormalities  and  compliance
roblems  in  JME,  the  investigated  hospital  cohort  represent
 selective  population  of  those  who  prefer  to  stay  in  outpa-
ient  care,  even  if  they  are  seizure-free  (Perini  et  al.,  1996;
rinka  et  al.,  2006;  Gelisse  et  al.,  2007;  De  Araújo  Filho
t  al.,  2008;  Baykan  et  al.,  2008;  Camﬁeld  and  Camﬁeld,
009).  Only  large  scale  prospective  multicenter  studies  with
ong  observational  periods  can  inform  clinicians  about  the
ong-term  course  and  help  determine  the  time  when  to  taper
ff  the  AED  treatment.  Further  prospective  controlled  stud-
es  are  needed  to  deﬁne  the  long-term  prognosis  with  and
ithout  AED  treatment  and  to  set  up  prognostic  factors.
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